James Nezamis

457 total citations
13 papers, 82 citations indexed

About

James Nezamis is a scholar working on Surgery, Epidemiology and Organic Chemistry. According to data from OpenAlex, James Nezamis has authored 13 papers receiving a total of 82 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 5 papers in Epidemiology and 3 papers in Organic Chemistry. Recurrent topics in James Nezamis's work include Eosinophilic Esophagitis (6 papers), Mycobacterium research and diagnosis (5 papers) and Microwave-Assisted Synthesis and Applications (3 papers). James Nezamis is often cited by papers focused on Eosinophilic Esophagitis (6 papers), Mycobacterium research and diagnosis (5 papers) and Microwave-Assisted Synthesis and Applications (3 papers). James Nezamis collaborates with scholars based in United States, Netherlands and Switzerland. James Nezamis's co-authors include Raphael Warshaw, Albert Miller, Gina Eagle, Evan S. Dellon, Gary W. Falk, Christoph Schlag, Alfredo J. Lucendo, Ikuo Hirano, Gail M. Comer and Alain Schoepfer and has published in prestigious journals such as Gastroenterology, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

James Nezamis

12 papers receiving 79 citations

Peers

James Nezamis
Sabina Sabharwal United States
Helen Harvey United States
Philip Alexander India
S Folkard United Kingdom
Mohamed Amine Lakmichi Morocco
Modupeola Diyaolu United States
Amrita Gaurav India
Jack W. Hu United States
Anna Mandelli Italy
Ana Messias Portugal
Sabina Sabharwal United States
James Nezamis
Citations per year, relative to James Nezamis James Nezamis (= 1×) peers Sabina Sabharwal

Countries citing papers authored by James Nezamis

Since Specialization
Citations

This map shows the geographic impact of James Nezamis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Nezamis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Nezamis more than expected).

Fields of papers citing papers by James Nezamis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Nezamis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Nezamis. The network helps show where James Nezamis may publish in the future.

Co-authorship network of co-authors of James Nezamis

This figure shows the co-authorship network connecting the top 25 collaborators of James Nezamis. A scholar is included among the top collaborators of James Nezamis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Nezamis. James Nezamis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Dellon, Evan S., Alfredo J. Lucendo, Christoph Schlag, et al.. (2022). Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial. Clinical Gastroenterology and Hepatology. 20(11). 2485–2494.e15. 34 indexed citations
2.
3.
Turner, Ralph M., Jeffrey M. Rohay, Gina Eagle, et al.. (2021). S458 Patient-Reported Symptom Improvement Following Treatment With APT-1011 in Patients with Eosinophilic Esophagitis as Measured by the PROSE: Results from FLUTE, A Phase 2b Clinical Trial. The American Journal of Gastroenterology. 116(1). S203–S203. 1 indexed citations
4.
Dellon, Evan S., Jeffrey M. Rohay, Ashley F. Slagle, et al.. (2020). Mo1184 AN EPISODE-BASED PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA EXPERIENCE IS FEASIBLE AND NOT BURDENSOME FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS. Gastroenterology. 158(6). S–818. 1 indexed citations
5.
6.
Dellon, Evan S., Alfredo J. Lucendo, Christoph Schlag, et al.. (2020). S0345 Safety and Efficacy of Long-Term Treatment of EoE With Fluticasone Propionate Orally Disintegrating Tablet (APT-1011): Results From 40 Weeks Treatment in a Phase 2b Randomized Double-Blind Placebo-Controlled Trial. The American Journal of Gastroenterology. 115(1). S169–S170. 2 indexed citations
7.
8.
9.
Griffith, David E., Gina Eagle, Rachel Thomson, et al.. (2018). Randomized Phase 3 Trial of Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) in Adult Patients. American Journal of Respiratory and Critical Care Medicine. 197. 1 indexed citations
10.
Winthrop, Kevin, Gina Eagle, Rachel Thomson, et al.. (2018). Six-Minute Walk Test (6MWT) Performance in Adult Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC). American Journal of Respiratory and Critical Care Medicine. 197.
11.
Winthrop, Kevin, Gina Eagle, Kozo Morimoto, et al.. (2018). EXTENSION STUDY OF AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT-REFRACTORY LUNG DISEASE CAUSED BY MYCOBACTERIUM AVIUM COMPLEX (MAC). CHEST Journal. 154(4). 182A–183A. 3 indexed citations
12.
Miller, Albert, Raphael Warshaw, & James Nezamis. (2013). Diffusing capacity and forced vital capacity in 5,003 asbestos‐exposed workers: Relationships to interstitial fibrosis (ILO profusion score) and pleural thickening. American Journal of Industrial Medicine. 56(12). 1383–1393. 15 indexed citations
13.
Hulsman, J.A.R.J., Christopher Banfield, Pascale Reidenberg, et al.. (1995). Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. Clinical Pharmacology & Therapeutics. 58(4). 383–389. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sabina Sabharwal Breakdown of academic impact, for papers by Helen Harvey Breakdown of academic impact, for papers by Philip Alexander Breakdown of academic impact, for papers by S Folkard Breakdown of academic impact, for papers by Mohamed Amine Lakmichi Breakdown of academic impact, for papers by Modupeola Diyaolu Breakdown of academic impact, for papers by Amrita Gaurav Breakdown of academic impact, for papers by Jack W. Hu Breakdown of academic impact, for papers by Anna Mandelli Breakdown of academic impact, for papers by Ana Messias
Rankless by CCL
2026